Imbria Pharmaceuticals is designing therapies to treat patients with life-altering cardiometabolic disorders by finding new treatments to enhance or restore how cells produce energy.Imbria’s lead program, ninerafaxstat, is currently in Phase 2 clinical development for conditions of oxygen deprivation in the heart. Ninerafaxstat is a partial inhibitor of fatty acid oxidation, designed to shift the balance of myocardial substrate utilization from fatty acids to glucose oxidation. This allows more ATP to be generated per unit oxygen increasing myocardial metabolic efficiency.

Imbria Pharmaceuticals

Founded: 2018
Location: Boston, MA
Employee range: 1 - 10
Clinical stage: Clin2
Therapy area: Non-obstructive hypertrophic cardiomyopathy
Drug types: CVV
Lead product: Ninerafaxstat

Drug notes:

About:

Jobs: